HRP20220407T1 - Pripravci i postupci za uporabu u liječenju homocistinurije - Google Patents

Pripravci i postupci za uporabu u liječenju homocistinurije Download PDF

Info

Publication number
HRP20220407T1
HRP20220407T1 HRP20220407TT HRP20220407T HRP20220407T1 HR P20220407 T1 HRP20220407 T1 HR P20220407T1 HR P20220407T T HRP20220407T T HR P20220407TT HR P20220407 T HRP20220407 T HR P20220407T HR P20220407 T1 HRP20220407 T1 HR P20220407T1
Authority
HR
Croatia
Prior art keywords
mutant polypeptide
isolated
peg
htcbs
dose
Prior art date
Application number
HRP20220407TT
Other languages
English (en)
Croatian (hr)
Inventor
Jan P. Kraus
Tomas Majtan
Erez Bublil
Original Assignee
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/935,690 external-priority patent/US9675678B2/en
Application filed by The Regents Of The University Of Colorado, A Body Corporate filed Critical The Regents Of The University Of Colorado, A Body Corporate
Publication of HRP20220407T1 publication Critical patent/HRP20220407T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20220407TT 2015-11-09 2016-11-09 Pripravci i postupci za uporabu u liječenju homocistinurije HRP20220407T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/935,690 US9675678B2 (en) 2013-01-29 2015-11-09 Compositions and methods for treatment of homocystinuria
EP16864878.0A EP3373922B1 (en) 2015-11-09 2016-11-09 Compositions and methods for use in the treatment of homocystinuria
PCT/US2016/061050 WO2017083327A1 (en) 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria

Publications (1)

Publication Number Publication Date
HRP20220407T1 true HRP20220407T1 (hr) 2022-05-27

Family

ID=58696136

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20220407TT HRP20220407T1 (hr) 2015-11-09 2016-11-09 Pripravci i postupci za uporabu u liječenju homocistinurije
HRP20241491TT HRP20241491T1 (hr) 2015-11-09 2016-11-09 Pripravci i metode za liječenje homocistinurije

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20241491TT HRP20241491T1 (hr) 2015-11-09 2016-11-09 Pripravci i metode za liječenje homocistinurije

Country Status (26)

Country Link
US (3) US11077175B2 (enExample)
EP (3) EP3373922B1 (enExample)
JP (2) JP7009364B2 (enExample)
KR (1) KR102819396B1 (enExample)
CN (2) CN108472277A (enExample)
AU (2) AU2016354030B2 (enExample)
BR (1) BR112018007768A2 (enExample)
CA (1) CA3001625A1 (enExample)
CY (1) CY1125113T1 (enExample)
DK (2) DK3373922T3 (enExample)
ES (2) ES2994256T3 (enExample)
FI (1) FI3998067T3 (enExample)
HR (2) HRP20220407T1 (enExample)
HU (2) HUE058749T2 (enExample)
IL (2) IL258487B2 (enExample)
LT (2) LT3373922T (enExample)
MX (1) MX2018005312A (enExample)
NZ (1) NZ741552A (enExample)
PL (2) PL3998067T3 (enExample)
PT (2) PT3373922T (enExample)
RS (2) RS63070B1 (enExample)
SG (1) SG10201912972SA (enExample)
SI (2) SI3998067T1 (enExample)
SM (2) SMT202200151T1 (enExample)
WO (1) WO2017083327A1 (enExample)
ZA (1) ZA201802376B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
ES2994256T3 (en) 2015-11-09 2025-01-21 Univ Colorado Regents Compositions and methods for treatment of homocystinuria
JP7146897B2 (ja) * 2017-04-17 2022-10-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト ホモシスチン尿症の治療のための酵素補充療法の最適化
PH12021553235A1 (en) 2019-06-26 2022-08-22 Univ Colorado Regents Drug product for enzyme therapy for treatment of homocystinuria
CN114630673A (zh) * 2019-09-03 2022-06-14 特拉维尔治疗瑞士有限公司 用于治疗升高的同型半胱氨酸水平的胱硫醚β-合成酶酶疗法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS555429A (en) * 1978-06-23 1980-01-16 Nissan Motor Co Ltd Pressure regulator for fuel injection type gasoline engine
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5656425A (en) 1993-08-17 1997-08-12 Regents Of The University Of Colorado Screening for mutations by expressing cDNA segments
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
AU721067B2 (en) 1995-04-25 2000-06-22 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
PL193352B1 (pl) 1998-04-28 2007-02-28 Applied Research Systems Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
US6174696B1 (en) 1999-11-12 2001-01-16 Genzyme Corporation Method for the determination of homocysteine
CA2377665A1 (en) 1999-07-06 2001-01-11 General Atomics Methods and compositions for assaying analytes
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20030091543A1 (en) 2001-10-26 2003-05-15 Klein Matthew B. Therapeutic cell preparation grafts and methods of use thereof
WO2003106971A2 (en) 2002-06-17 2003-12-24 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) * 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
KR20060065663A (ko) 2003-07-31 2006-06-14 안티캔서, 인코포레이티드 생체 내에서의 유효성 향상을 위한, ＰＥＧ-ｒＭＥＴ아제와조합된 ＰＬＰ의 용도
CN1552905A (zh) 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070010492A1 (en) 2005-07-11 2007-01-11 Generale Robert J Composition and method for reducing homocysteine caused by drugs containing methyl compounds
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
JP6041454B2 (ja) * 2007-03-15 2016-12-07 株式会社 Ｄｎａセキュリティー研究所 Ｄｎａ含有インク組成物
JP5074146B2 (ja) 2007-03-30 2012-11-14 オリンパス株式会社 カプセル型医療装置
CN101322840A (zh) 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
CN102791856B (zh) 2010-02-04 2016-12-07 艾莫瑟有限公司 用甲硫氨酸-γ-裂合酶加工的酶和其药理学制备物
JP2013532166A (ja) 2010-07-01 2013-08-15 アイシス イノベーション リミテッド 認知障害の治療
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
WO2015033279A1 (en) * 2013-09-04 2015-03-12 Mahesh Kandula Compositions and methods for the treatment of homocystinuria
US11123436B2 (en) 2015-07-24 2021-09-21 Hanmi Pharm. Co., Ltd. Method of preparing physiologically active polypeptide conjugate
ES2994256T3 (en) 2015-11-09 2025-01-21 Univ Colorado Regents Compositions and methods for treatment of homocystinuria
JP7146897B2 (ja) * 2017-04-17 2022-10-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト ホモシスチン尿症の治療のための酵素補充療法の最適化
JP7002314B2 (ja) * 2017-12-13 2022-02-10 株式会社ブリヂストン 空気入りタイヤ
PH12021553235A1 (en) 2019-06-26 2022-08-22 Univ Colorado Regents Drug product for enzyme therapy for treatment of homocystinuria
CN114630673A (zh) 2019-09-03 2022-06-14 特拉维尔治疗瑞士有限公司 用于治疗升高的同型半胱氨酸水平的胱硫醚β-合成酶酶疗法

Also Published As

Publication number Publication date
AU2016354030B2 (en) 2022-09-15
EP3373922A1 (en) 2018-09-19
LT3998067T (lt) 2024-11-25
JP2022050589A (ja) 2022-03-30
IL258487B2 (en) 2023-09-01
AU2022287540B2 (en) 2025-02-27
SMT202400463T1 (it) 2025-01-14
US20240091325A1 (en) 2024-03-21
US20220125896A1 (en) 2022-04-28
DK3998067T3 (da) 2024-10-28
US11077175B2 (en) 2021-08-03
US20200276282A1 (en) 2020-09-03
EP4487914A2 (en) 2025-01-08
EP3998067B1 (en) 2024-09-11
RS66106B1 (sr) 2024-11-29
SI3998067T1 (sl) 2025-03-31
ES2909914T3 (es) 2022-05-10
LT3373922T (lt) 2022-04-11
IL258487B1 (en) 2023-05-01
HUE058749T2 (hu) 2022-09-28
AU2022287540A1 (en) 2023-02-02
CN115920016A (zh) 2023-04-07
CY1125113T1 (el) 2024-02-16
PT3998067T (pt) 2024-11-04
JP2018532763A (ja) 2018-11-08
JP7009364B2 (ja) 2022-02-10
US12194082B2 (en) 2025-01-14
ES2994256T3 (en) 2025-01-21
BR112018007768A2 (pt) 2018-10-23
JP7482914B2 (ja) 2024-05-14
EP3998067A1 (en) 2022-05-18
EP3373922B1 (en) 2022-01-05
HUE068830T2 (hu) 2025-01-28
NZ741552A (en) 2022-04-29
PL3998067T3 (pl) 2025-01-07
EP3373922A4 (en) 2019-05-15
KR20180074703A (ko) 2018-07-03
CA3001625A1 (en) 2017-05-18
PL3373922T3 (pl) 2022-05-02
PT3373922T (pt) 2022-03-28
HRP20241491T1 (hr) 2025-01-03
FI3998067T3 (fi) 2024-10-31
EP4487914A3 (en) 2025-03-26
SI3373922T1 (sl) 2022-05-31
CN108472277A (zh) 2018-08-31
SMT202200151T1 (it) 2022-05-12
DK3373922T3 (da) 2022-03-28
AU2016354030A1 (en) 2018-05-10
ZA201802376B (en) 2020-11-25
SG10201912972SA (en) 2020-03-30
HK1258502A1 (en) 2019-11-15
MX2018005312A (es) 2018-08-15
IL258487A (en) 2018-05-31
WO2017083327A1 (en) 2017-05-18
US11771745B2 (en) 2023-10-03
IL302198A (en) 2023-06-01
KR102819396B1 (ko) 2025-06-12
RS63070B1 (sr) 2022-04-29

Similar Documents

Publication Publication Date Title
HRP20220407T1 (hr) Pripravci i postupci za uporabu u liječenju homocistinurije
HRP20240050T1 (hr) Formulacije tpp1 i postupci liječenja bolesti cln2
HRP20191966T1 (hr) Stabilizirani neproteinski klostridijalni pripravci toksina
JP2015525763A5 (enExample)
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BRPI0408490A (pt) composições que compreendem ácidos graxos e aminoácidos
JP2010248207A5 (enExample)
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
ME02865B (me) C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
HRP20121033T1 (hr) Praškasta formulacija za valganciklovir
BR112021026292A2 (pt) Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria
JP2017533201A5 (enExample)
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
JP2018532763A5 (enExample)
HRP20192246T1 (hr) Marker za poremećaje kisele sfingomijelinaze i njegova uporaba
US10881701B2 (en) Method for providing support during vaccinations and during adaptive immune system response
MX2022004944A (es) Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas.
SI3099307T1 (en) Use of cladribine for the treatment of neuromyelitis of the visual nerve
FI3634396T3 (fi) Koostumus L-DOPA-hoidon tehon parantamiseen
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
HRP20150363T1 (hr) Kompozicije koje sadrže core-1 pozitivni mikroorganizam i njihova primjena za lijeäśenje ili profilaksu tumora
EP2604264A1 (en) Pharmaceutical composition for treating viral diseases
JP2020531586A (ja) 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物